NT-proBNP levels on admission predicts pulmonary hypertension persistence in patients with acute pulmonary embolism  by Vavera, Zdeněk et al.
Available online at www.sciencedirect.comjournal homepage: www.elsevier.com/locate/crvasa
C O R E T VA S A 54 ( 2012 ) e27 –e310010-8650/$ - see fro
doi:10.1016/j.crvasa
nCorresponding a
E-mail address: vNT-proBNP levels on admission predicts pulmonary
hypertension persistence in patients with acute
pulmonary embolismZdeneˇk Vaveraa, Jan Voj acˇeka,n, Radek Pudila, Jaroslav Maly´b, Pavel Eli asˇc
a1st Department of Cardiovascular Medicine, Medical Faculty of Charles University and University Hospital, Hradec Kralove, Czech Republic
b2nd Department of Internal Medicine – Department of Clinical Hematology, Medical Faculty of Charles University and University Hospital,
Hradec Kralove, Czech Republic
cDepartment of Radiology, Medical Faculty of Charles University and University Hospital, Hradec Kralove, Czech Republica r t i c l e i n f o
Article history:
Received 29 December 2011
Received in revised form
20 January 2012
Accepted 23 January 2012
Keywords:
Pulmonary embolism
Chronic thromboembolic
pulmonary hypertension
Risk factorsnt matter & 2012 The Cze
.2012.01.010
uthor. Tel.: þ420 495 832
ojacjan@fnhk.cz (J. Voj acˇa b s t r a c t
Background: Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare, but due to its
unfavorable prognosis, feared complication of thromboembolic disease. We assessed the
incidence and risk factors for pulmonary hypertension (PH) in a cohort of consecutive patients
admitted with pulmonary embolism to the tertiary University Hospital.
Methods: In our cohort of 120 consecutive patients with proved pulmonary embolism (PE) we
studied the course of biochemical and echocardiographic parameters with regard to risk
factors predicting pulmonary hypertension at the end of hospitalization.
Results: Echocardiographic signs of pulmonary hypertension were present at the time of
discharge in more than one half (50.8%) of patients admitted with pulmonary embolism.
Predictors of persisting pulmonary hypertension were initial pulmonary hypertension, high
initial NT-proBNP levels and age.
Conclusion: Residual pulmonary hypertension at discharge was present in 50.8% cases, at this
time there was a strong relationship between PH and elevated NT-proBNP on admission. The
patients will be followed-up and possible development of CTPEH will be evaluated at 6, 12 and
24-month period.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z.o.o. All
rights reserved.1. Introduction
Data on the incidence of chronic thromboembolic pulmonary
hypertension (CTEPH) after pulmonary embolism are inconsis-
tent. Relevant studies of patients surviving symptomatic pul-
monary embolism showed CTEPH incidence in the range of
0,1%–8% [1–6]. In our paper we give our first results from mid-
term study, which was designed to evaluate possibilities
of CTEPH prediction in a population of consecutive patients
with pulmonary embolism, admitted to tertiary cardiological
department.ch Society of Cardiology.
248; fax: þ420 495 832 006
ek)1.1. Population and methods
Altogether 163 patients older than 18 years with proved diagnosis
of pulmonary embolism were hospitalized in our Department
from July 2007 to March 2010. All of them were admitted without
undue delay through Emergency Department of our hospital, or
directly from the field. Diagnosis was based on multidetector
computer tomography angiogram (CTA) using Siemens Somatom
Emotion 6 (except one case diagnosed on perfusion scintigraphy
in patient with iodine allergy and one case, where diagnosis
was based on history, clinical presentation, positive duplexPublished by Elsevier Urban & Partner Sp.z.o.o. All rights reserved.
.
Table 1 – Study population characteristics.
Number of patients 120
Age (years) 57.9716.2
Female (n (%)) 60 (50)
BMI (kg/m2) 29.275.48
Systolic blood pressure (mm Hg) 135723.7
Diastolic blood pressure (mm Hg) 80.6714.1
Smoker (n (%)) 21 (17.5)
Steroid hormones user (n (%)) 24 (20)
History of trauma/surgery/
immobilization (n (%))
13 (10.8)/13 (10.8)/15
(12.5)
Oncological disease (n (%)) 17 (14.2)
Thrombophilia (known or newly
detected) (n (%))
15 (12.5)
NT-proBNP (pmol/l) 2467490
Troponin T (mg/l) 0.03170.0462
Echocardiography on admission
RV diameter (mm) 31.474.51
PAsP (mm Hg) 50.8 717.7
TAPSE (mm) 20.574.64
SaTri (cm/s) 12.372.65
Echocardiography at discharge
RV diameter (mm) 29.673.93
PAsP (mm Hg) 37.8711.5
TAPSE (mm) 23.174.02
SaTri (cm/s) 13.072.21
Table 2 – Clinical presentation of pulmonary embolism
patients.
Dyspnea (%) 94.1
Chest pain (%) 48.5
Lower limb swelling (%) 44.1
Cough (%) 37.5
Syncope, presyncope (%) 30.1
Hemoptysis (%) 3.7
ECG signs of PE (%) 39.7
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admission blood samples were assessed to determine troponin-
T (TnT) and N-terminal fragments of brain natriuretic peptide
precursor (NT-proBNP) levels (electrochemoluminiscent method
on Elexis device (Roche company)), a D-dimer (imunoturbidi-
metric method on device Compact a STA-R (Stago company)).
Within first 24 h echocardiography was carried out (on PHILIPS
SONOS 5500 or GE Vivid 7) by the standard way, especially
focused to right ventricle (RV) diameter in parasternal long axis,
signs of RV systolic dysfunction (systolic excursion of lateral part
of tricuspid annulus (TAPSE), peak velocity of this movement
(SaTri), RV free wall hypokinesis, RV dilatation) and pulmonary
artery systolic pressure estimation based on peak tricuspid
regurgitation jet velocity and right atrium pressure according to
respiratory variations of vena cava inferior.
Follow-up was offered to all patients, involving, in con-
formity with study design, re-assessing TnT and NT-proBNP
before discharge (usually 7–10 days since admission), if they
were initially elevated, and echocardiography in the same
interval. Next echocardiographic examination is planned in 6,
12 and 24 months since acute stage, and 6-months visit also
included pulmonary CTA. This will be the subject of our next
report. Agreement with such a dispensarisation was con-
firmed by signing of Informed consent, endorsed by the Local
Ethical committee.
From the total 163 patients—2 died early (on the 2nd and
4th hospitalization day). Of the remaining 161 we included
120 patients into our study (60 males, 60 females, age 19–85,
mean 57.9716.2 years). Reasons for exclusion were patient’s
refusal to long-term follow-up (7 patients), missing data
(insufficient echocardiographical imaging, diagnosis made in
another medical facility, early transfer to regional hospital)
(8 patients), combined pulmonary hypertension aetiology
(8 patients), apparent follow-up noncompliance or terminal
stage of associated disease (7 patients). Eleven patients had
recurrence of thromboembolism (5 males, 6 females), this
group of patients was also excluded from our analysis.
Obtained data were tested for distribution normality, for
statistical analysis paired t-test or Wilcoxon’s test was used.
Correlation between variables was assessed by Pearson and
Spearman’s analysis.2. Results
The demographic characteristics of our study group are given
in Table 1. The following symptoms were present on
admission: dyspnea in 111 patients (92.5%), chest pain in 62
patients (51.7%), lower limb swelling in 52 patients (43.3%),
cough in 46 patients (38.3%), syncope or presyncope in 33
patients (27.5%) and hemoptysis in 4 patients (3.3%). ECG
signs of pulmonary embolism was found in 44 cases (36.7%)
(Table 2). A remarkable fact is the D-dimer test negativity in 2
patients (1.7%).
According to pulmonary CTA the radiologist described an
extensive pulmonary embolism in 43 patients (35.8%). But
criteria of clinically massive (based on guidelines of Czech
Society of Cardiology [7]) or high-risk (based on guidelines of
European Society of Cardiology [8]) pulmonary embolism was
met by only 5 (4.2%) patients. Acute small pulmonaryembolism, i.e. low-risk PE had 19 (15.8%) patients. Remaining
96 (80.0%) cases were classified as submassive, i.e. intermedi-
ate-risk pulmonary embolism because of either RV dilatation,
or RV dysfunction (based on echocardiography and/or ele-
vated NT-proBNP), or RV damage (in case of TnT positivity) or
their combination (Table 3).
Altogether 107 patients (81.2%) were treated with unfrac-
tionated heparin or low-molecular weight heparin, followed
by vitamin K antagonist (warfarin) until therapeutic and
stable levels of international normalized ratio (INR) were
achieved. In 13 cases (10.8%) thrombolysis (alteplase) was
administrated with concomitant parenteral administration of
unfractionated heparin, followed by the above mentioned
anticoagulant treatment. All patients were discharged with
therapeutic doses of anticoagulation therapy.
Risk factors present in our patient cohort are shown in Table 4.
Trauma, traveling, immobilization, previous surgery, steroid
hormone therapy were considered as transient risk factors.
Fig. 1 – Relationship between admission and discharge
pulmonary artery systolic pressure.
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oncological disease are listed. Coincidence of permanent and
transient risk factors in our study group was noted in 15 cases.
At the time of admission there was RV dysfunction in 83
(69.2%), interventricular septum applanation (D-shaped left
ventricle) in 48 (40%) and echocardiographic signs of pulmon-
ary hypertension in 95 (79.2%) patients.
Echocardiography at the time of discharge (mean 8 day)
revealed lasting RV dysfunction in 60 (50%) patients and
residual pulmonary hypertension was detected in 61 (50.8%)
(Table 5).
During hospitalization there was a statistically significant
(p ¼ 0.0014) decrease of RV diameter, estimated pulmonary
artery systolic pressure, improvement of RV function para-
meters and significant decrease of NT-proBNP levels.
Pulmonary hypertension persistence at the time of dis-
charge correlated with some variables on admission. A strong
correlation was found between discharge PAsP and initial
PAsP (Fig. 1). Also a positive correlation with initial NT-proBNP
(Fig. 2), and age was found. Considering all variables obtained
at the time before discharge, there was a correlation between
elevated pulmonary artery systolic pressure and persisting
elevation of NT-proBNP and RV dilatation. Despite the
relationship between discharge PH and elevated NT-proBNP
as a marker of RV dysfunction, there was surprisingly no
correlation with either echocardiographic signs of RV dys-
function, or reduction rate of RV diameter or PAsP during
hospitalization, as shown in Table 6.Table 4 – Patients with transient and permanent risk
factors (RF) and with idiopathic thromboembolism.
Transient RF Permanent RF Idiopathic cases
58 (38.3%) 31 (25.8%) 46 (38.3%)
Table 5 – Means and standard deviations (7values) of RV
diameter, pulmonary artery systolic pressure (PAsP),
TAPSE, SaTri and NT-proBNP on admission and at the
discharge time.
Vstupneˇ Prˇed dimisı´
PK 31.72 (74.86) 29.8 (74.03)
PAsP 53.0 (718.9) 39.2 (712.0)
TAPSE 20.2 (74.59) 22.6 (73.98)
Sa 12.2 (72.58) 13.1 (72.21)
NT-proBNP 297 (7552) 69.3 (7205)
Fig. 2 – Relationship between NT-proBNP levels on
admission and pulmonary artery systolic pressure at the
time of discharge.
Table 3 – Risk stratification of study population.
Massive PE Submassive PE Acute small PE
3.7% 81.6% 14.7%
Table 6 – Correlation of echocardiographic signs of
discharge pulmonary hypertension with particular vari-
ables.
Correlation
coefficient
Level of
signifficance
Initial PAsP 0.701 o0.0000005
Initial NT-proBNP 0.443 o0.0000005
Age 0.46 o0.0000005
Discharge NT-proBNP 0.42 o0.0000005
Discharge RV
diameter
0.42 o0.000001
Initial TAPSE 0.033 o0.05
Initial SaTri 0.103 o0.05
RV diameter
difference
0.083 o0.05
PaSP difference 0.071 o0.053. Discussion
During the last few years we can see an increasing attention
to pulmonary circulation diseases. New specific treatment
modalities are coming hand in hand with this interest and as
Table 7 – CTEPH incidence data.
CTEPH incidence
Fedullo PF (2001) [1] 0.1–0.5%
Becattini C (2006) [2] 0.8% (1.5% idiopathic PE) (n ¼ 259)
Miniati M (2006) [3] 1% (n ¼ 320)
Pengo V (2004) [4] 3.8% (n ¼ 223)
Ribeiro (1999) [5] 5.1% (n ¼ 78)
Dentali F (2009) [6] 8.8% (n ¼ 91)
Table 8 – CTEPH risk factors (based on [19,20]).
History of thromboembolic event, especially recurrent
Idiopathic PE
History of oncology disease
Extensive lung perfusion defects, massive PE
Pulmonary hypertension persistence 5 weeks since acute PE
Atrio-ventricular shunts
Central venous catheter or intracardiac pacemaker electrodes
History of splenectomy
Antiphospholipid syndrome, increased factor VIII
Hypothyreosis and thyreoidal substitution therapy
Chronic inflammatory diseases (e.g. nonspecific bowel
inflammations, osteomyelitis)
Blood group different from 0
Increased levels of plasmatic lipoprotein (a)
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and quality of life of those patients, who are indicated for
such a therapy, especially if they are indicated early.
With the exception of patients, in whom pulmonary
embolism is a complication of another underlying disease
with unfavorable prognosis, the major adverse prognostic
factor after an acute pulmonary embolism is a development
of chronic thromboembolic pulmonary hypertension. The
aim of our mid- and long-term prospective follow-up of
consecutive patients surviving pulmonary embolism is the
focus on CTEPH risk factors and incidence. We are using
routinely obtainable variables (anamnestic, clinical, labora-
tory and morphologic (echocardiography and pulmonary CTA)
data). In this paper we present discharge characteristics of
our cohort and some initial implications.
Up to now, the incidence of CTEPH in survivors of
pulmonary embolism is not well defined. More accurate
prediction is complicated due to several reasons. One of
them is the fact that one half of patients with angiographi-
cally documented CTEPH have no history of venous throm-
boembolism [9,10], which corresponds to the finding that only
one half of patients with PE are properly diagnosed and
treated. In addition two-thirds of patients with deep venous
thrombosis have perfusion lung scintigraphy defects without
any PE symptoms [11].
Thromboembolic material in pulmonary vascular bed is in
almost all cases early (in experiment within 4–6 weeks)
[12–14] resolved by fibrinolytic system. In clinical trials there
is a slow resolution of perfusion defects at pulmonary
perfusion scintigraphy and so called ‘‘stable phase’’ is reached
in about 2 months in 90% of patients [5]. Perfusion defects
persistence after 3 months of anticoagulant therapy are
described in two-thirds of patients [15].
CTEPH rises from incomplete dissolution and organization
of thromboembolic masses, which lead to persistent pul-
monary vascular bed obstruction. But pulmonary embolism is
believed to be a trigger of subsequent functional and
morphological changes in pulmonary arteries wall, which
are exposed to increased wall shear stress, but even in those it
is situated distally, beyond the obstruction [16,17]. The
changes include vascular smooth muscle hypertrophy, in-
timal thickening and fibrotisation and plexiform lesions
formation. Plexiform lesions are organized and recanalised
aneurysmatic spots of small pulmonary artery branches
proximally and even distally to obstructed areas as a reaction
to increased wall shear stress and endothelial proliferation
[18]. These changes are identical with pattern which can be
seen in patients with pulmonary arterial hypertension. Thus,
they represent nonspecific small pulmonary arterial wall
reaction to chronically increased pulmonary artery pressure,
which ultimately contributes to further hemodynamic wor-
sening. Additional mechanism of increased pulmonary vas-
cular resistance is an in-situ thrombosis, and/or pulmonary
embolus extension to unobstructed areas. Another possibility
is also embolisation of partially organized emboli, which
could not be dissolved by endogenic or pharmacologic
fibrinolysis.
RV is chronically exposed to inappropriate pressure over-
load. It becomes hypertrophic, and afterwards dilates. Sec-
ondary insufficiency of tricuspid valve contributes to furtherdeterioration by RV volume overload. When compensation
mechanisms are exhausted, right ventricular failure evolves.
From so far existing CTEPH incidence data (Table 7), the most
convincing and accepted is the Swedish study, in which CTEPH
incidence during 2 years of follow-up in PE survivors was 3.8%
[4]. Known CTEPH risk factors are summarized in Table 8.
If there is not any other comorbidity with adverse prognosis,
the outcome is determined mainly by the degree of pulmonary
hypertension. Values above 30 mm Hg are prognostically
unfavorable, especially with concomitant right ventricular fail-
ure. On the other hand, prognostically nonsignificant are the
number of PE recurrences, their extent and localization [21].
The incidence of CTEPH in the survivors of pulmonary
embolism is not clear. It is difficult to obtain more accurate
data due to several factors. Almost one half of patients with
CTEPH have no history of venous thromboembolism and in
30% of patients with CTEPH there is no history of pulmonary
embolism [22].
In our own cohort of patients with PE echocardiographic,
signs of pulmonary hypertension at discharge time were
present in more than one-half of patients. Respecting recent
guidelines those patients should be dispensarised with the
focus to possible CTEPH development. According to our
results pulmonary hypertension persistence at the time of
discharge can be predicted also from high initial NT-proBNP
levels and echocardiographic signs of pulmonary hyperten-
sion on admission, especially in the elderly patients. Residual
pulmonary hypertension at discharge was present in 50.8%
cases in our study population, at this time there was a
strong relationship between PH and elevated NT-proBNP.
CO R E T VA S A 54 ( 2012 ) e27 –e31 e31The development of CTEPH cannot be estimated in such a
short time after acute PE; patients will be followed-up and
possible development of CTPEH will be evaluated at 6, 12 and
24-month period.
Possible limitation of our study is that our cohort is
relatively small due to monocentricity and therefore further
evaluation on multicenter basis may be warranted.Acknowledgments
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